NCT06638931 2026-04-15ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Recruiting28 enrolled
NCT03556228 2025-12-11VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaVM Oncology, LLCPhase 1/2 Recruiting242 enrolled